Efficacy and Safety of Tiotropium in Patients With COPD and Concomitant Diagnosis of Asthma [clinicaltrials:NCT00152984]

Bio2RDF uri

Efficacy and Safety of Tiotropium in Patients With COPD and Concomitant Diagnosis of Asthma [clinicaltrials:NCT00152984]

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

http://bio2rdf.org/clinicaltrials:NCT00152984

Bio2RDF identifier

NCT00152984

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00152984

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT00152984

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:cb0c361eb08868684577f62e437d822b

brief summary [clinicaltrials_vocabulary:brief-summary]

The primary objective o ...... ncomitant diagnosis of asthma

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Efficacy and Safety of Tiotrop ...... oncomitant Diagnosis of Asthma

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

AUC(0-6) FEV1 (Area under the curve of change in FEV1 from baseline to 6 hours post dose) after 12 weeks of treatment [clinicaltrials_resource:6756ac3aa5178e66d85da6d9b27d2e59]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

AUC(0-6) FEV1 (Area under the curve of change in FEV1 from baseline to 6 hours post dose) after 12 weeks of treatment [clinicaltrials_resource:049cf30e2bb75fc3fd1a23f2ad1ed423]

AUC(0-6) FEV1 (Area under the curve of change in FEV1 from baseline to 6 hours post dose) after 12 weeks of treatment [clinicaltrials_resource:1465fc8edae74ef407109317782fdbbe]

AUC(0-6) FEV1 (Area under the curve of change in FEV1 from baseline to 6 hours post dose) after 12 weeks of treatment [clinicaltrials_resource:38ed682d819b0403e9cd93ec8caf77cf]

AUC(0-6) FEV1 (Area under the curve of change in FEV1 from baseline to 6 hours post dose) after 12 weeks of treatment [clinicaltrials_resource:4960c27590b3e1cf69cc0bd22878dd67]

AUC(0-6) FEV1 (Area under the curve of change in FEV1 from baseline to 6 hours post dose) after 12 weeks of treatment [clinicaltrials_resource:541312605224ff29a696bee5e126d36d]

AUC(0-6) FEV1 (Area under the curve of change in FEV1 from baseline to 6 hours post dose) after 12 weeks of treatment [clinicaltrials_resource:728087877a33ccdeedc81b54d877928a]

AUC(0-6) FEV1 (Area under the curve of change in FEV1 from baseline to 6 hours post dose) after 12 weeks of treatment [clinicaltrials_resource:87ee3443f11b9e7dc56cb61cf9e310b6]

AUC(0-6) FEV1 (Area under the curve of change in FEV1 from baseline to 6 hours post dose) after 12 weeks of treatment [clinicaltrials_resource:a912c730c901e0591f25a99e225ce080]

AUC(0-6) FEV1 (Area under the curve of change in FEV1 from baseline to 6 hours post dose) after 12 weeks of treatment [clinicaltrials_resource:b147f0f84d775e33fed3b8b6898ac1fa]

AUC(0-6) FEV1 (Area under the curve of change in FEV1 from baseline to 6 hours post dose) after 12 weeks of treatment [clinicaltrials_resource:b1b6268783e8c2814a713fb7f90a4552]

completion date [clinicaltrials_vocabulary:completion-date]

2006-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00152984 [clinicaltrials_resource:1e4d78e3cbd308da409031c8c1b4e474]

enrollment [clinicaltrials_vocabulary:enrollment]

472

http://www.w3.org/2001/XMLSchema#integer

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2005-09-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

Tiotropium inhalation capsules [clinicaltrials_resource:0d41ffb5e6328ba5836ed3317e688940]

Placebo inhalation capsules [clinicaltrials_resource:5c0b206f8a0f18ae3d924ae42517d191]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Tiotropium [clinicaltrials_resource:17b37513b438cefbf8247a55601652f1]

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2013-10-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Boehringer Ingelheim [clinicaltrials_resource:5d012cfae6e8b67d8437e7145ea9a68f]

link [clinicaltrials_vocabulary:link]

[clinicaltrials_resource:c68906fb0873798d242c1a8bb902ff0e]

[clinicaltrials_resource:f4f4fb5dffa140bc9bc408a5851b3bc5]

location [clinicaltrials_vocabulary:location]

CHU Sart Tilman [clinicaltrials_resource:a0ec433b135656fb17d5c330ddd58c26]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00152984

http://www.w3.org/2001/XMLSchema#string

official title [clinicaltrials_vocabulary:official-title]

A 12-week Randomised, Double B ...... oncomitant Diagnosis of Asthma

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

2,0530099487304687e+2

http://www.w3.org/2001/XMLSchema#float

overall official [clinicaltrials_vocabulary:overall-official]

Boehringer Ingelheim Study Coordinator [clinicaltrials_resource:f30f851c5673a671c8601054b895cda2]

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

Belgium: Ministry of Social Affairs, Public Health and the Environment [clinicaltrials_resource:d3ddb1abccd33f65f5716f209988a5fc]

phase [clinicaltrials_vocabulary:phase]

Phase 4 [clinicaltrials_resource:ec41833bc88cd90619c4d85c549688bd]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2006-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

source [clinicaltrials_vocabulary:source]

Boehringer Ingelheim [clinicaltrials_resource:5d012cfae6e8b67d8437e7145ea9a68f]

start date [clinicaltrials_vocabulary:start-date]

2004-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00152984 study design [clinicaltrials_resource:747ec47e41c54a50c4505d62f7b944dd]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00152984

verification date [clinicaltrials_vocabulary:verification-date]

2013-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00152984

http://www.w3.org/2001/XMLSchema#string

title

Efficacy and Safety of Tiotrop ...... oncomitant Diagnosis of Asthma

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

Efficacy and Safety of Tiotrop ...... a [clinicaltrials:NCT00152984]

@en